114 related articles for article (PubMed ID: 20003833)
1. beta-Tubulin III mRNA expression and docetaxel sensitivity in non-small cell lung cancer.
Wang LF; Yin HT; Qian XP; Wei J; Zhao Y; Yu LX; Liu BR
Clin Invest Med; 2009 Dec; 32(6):E278. PubMed ID: 20003833
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
Wang L; Wei J; Qian X; Yin H; Zhao Y; Yu L; Wang T; Liu B
BMC Cancer; 2008 Apr; 8():97. PubMed ID: 18402708
[TBL] [Abstract][Full Text] [Related]
3. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.
Hasegawa S; Miyoshi Y; Egawa C; Ishitobi M; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Aug; 9(8):2992-7. PubMed ID: 12912947
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.
Urano N; Fujiwara Y; Doki Y; Kim SJ; Miyoshi Y; Noguchi S; Miyata H; Takiguchi S; Yasuda T; Yano M; Monden M
Int J Oncol; 2006 Feb; 28(2):375-81. PubMed ID: 16391792
[TBL] [Abstract][Full Text] [Related]
5. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer.
Hayashi Y; Kuriyama H; Umezu H; Tanaka J; Yoshimasu T; Furukawa T; Tanaka H; Kagamu H; Gejyo F; Yoshizawa H
Intern Med; 2009; 48(4):203-8. PubMed ID: 19218769
[TBL] [Abstract][Full Text] [Related]
6. The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin.
He W; Zhang D; Jiang J; Liu P; Wu C
Med Oncol; 2014 May; 31(5):950. PubMed ID: 24722794
[TBL] [Abstract][Full Text] [Related]
7. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
[TBL] [Abstract][Full Text] [Related]
8. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions.
Xie L; Chen X; Wang L; Qian X; Wang T; Wei J; Yu L; Ding Y; Zhang C; Liu B
BMC Cancer; 2010 Oct; 10():591. PubMed ID: 21029414
[TBL] [Abstract][Full Text] [Related]
9. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel.
Shalli K; Brown I; Heys SD; Schofield AC
FASEB J; 2005 Aug; 19(10):1299-301. PubMed ID: 15946994
[TBL] [Abstract][Full Text] [Related]
10. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
Monzó M; Rosell R; Sánchez JJ; Lee JS; O'Brate A; González-Larriba JL; Alberola V; Lorenzo JC; Núñez L; Ro JY; Martín C
J Clin Oncol; 1999 Jun; 17(6):1786-93. PubMed ID: 10561216
[TBL] [Abstract][Full Text] [Related]
12. Effect of docetaxel on expression of eIF3a in human lung cancer A549 cell line.
Gong Z; Xu X; Hou R; Guo Y; Sheng F; Ouyang D; Zhou H; Liu Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):771-6. PubMed ID: 20818067
[TBL] [Abstract][Full Text] [Related]
13. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial.
Dancey J; Shepherd FA; Gralla RJ; Kim YS
Lung Cancer; 2004 Feb; 43(2):183-94. PubMed ID: 14739039
[TBL] [Abstract][Full Text] [Related]
14. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
15. Absence of beta-tubulin gene mutation in gastric carcinoma.
Urano N; Fujiwara Y; Hasegawa S; Miyoshi Y; Noguchi S; Takiguchi S; Yasuda T; Yano M; Monden M
Gastric Cancer; 2003; 6(2):108-12. PubMed ID: 12861402
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer.
Szczyrek M; Mlak R; Krawczyk P; Wojas-Krawczyk K; Powrózek T; Szudy-Szczyrek A; Zwolak A; Daniluk J; Milanowski J
Pathol Oncol Res; 2017 Jul; 23(3):607-614. PubMed ID: 27988838
[TBL] [Abstract][Full Text] [Related]
17. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.
Veitia R; Bissery MC; Martinez C; Fellous A
Br J Cancer; 1998 Oct; 78(7):871-7. PubMed ID: 9764577
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
19. Expression of β-tubulin III and survivin in advance stage breast cancer correlates with chemotherapeutic effects of docetaxel.
Yuan SF; Zhu LJ; Zheng WE; Chen H; Wu LL; Zhang W; Sun HY; Chen WJ
Asian Pac J Cancer Prev; 2012; 13(1):361-5. PubMed ID: 22502701
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between BRCA1 mRNA expression in tumor cells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions].
Qian XP; Liu BR; Jiang M; Hu J; Yu LX; Wang LF; Hu WJ; Zou ZY
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):457-60. PubMed ID: 21875488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
